Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIb Study of Personalized Neoantigen Peptide-Based Cancer Vaccine for Patients With Solid Tumors

NCT06614140 is registered in ClinicalTrials.gov with Seqker Biosciences, Inc. as lead sponsor.

NCT NCT06614140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06614140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIb Study of Personalized Neoantigen Peptide-Based Cancer Vaccine for Patients With Solid Tumors
Lead sponsor
Seqker Biosciences, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 24, 2022
Completion date
August 15, 2025
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, solid tumor, adult